




RealRate

MEDICINAL PRODUCTS 2018

ARCA biopharma Inc.
Rank 39 of 49





RealRate

MEDICINAL PRODUCTS 2018

ARCA biopharma Inc.
Rank 39 of 49



The relative strengths and weaknesses of ARCA biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARCA biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 267% points. The greatest weakness of ARCA biopharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 188% points.

The company's Economic Capital Ratio, given in the ranking table, is -135%, being 113% points below the market average of -22%.

Input Variable	Value in 1000 USD
Assets, Current	12,299
Assets, Non-Current	24
General and Administrative Expense	4,636
Goodwill	0
Liabilities, Current	2,070
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	17
Other Expenses	-55
Other Liabilities	20
Other Net Income	0
Other Revenues	167
Property, Plant and Equipment, Net	42
Research and Development	14,076

Output Variable	Value in 1000 USD
Liabilities	2,090
Assets	12,365
Expenses	18,657
Revenues	167
Stockholders Equity	10,275
Net Income	-18,490
Comprehensive Net Income	-18,482
Economic Capital Ratio	-135%